CPI-613 (devimistat) + Cytarabine/Mitoxantrone
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Key Facts
Indication
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase
Phase 3
Status
Active, not recruiting
Company
About Rafael Holdings
Rafael Holdings is a clinical-stage biotech focused on developing novel oncology and rare disease therapeutics. Its core mission is to improve and extend the lives of patients with difficult-to-treat diseases by targeting cancer metabolism and lysosomal function. The company's strategy leverages its lead asset, devimistat, in late-stage trials for solid tumors and hematologic malignancies, while integrating new platforms through strategic mergers. With two Phase 3 trials ongoing and a recent expansion into rare diseases, Rafael is transitioning from a clinical-stage entity toward a potential commercial enterprise.
View full company profileTherapeutic Areas
Other Relapsed or Refractory Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Phase 1B/2A |
| Annamycin (AnnAraC) | Moleculin Biotech | Phase 3 |